124 related articles for article (PubMed ID: 12824802)
1. The effect of lamivudine on the replication of hepatitis B virus in HIV-infected patients depends on the host immune status (CD4 cell count).
Haverkamp M; Smit M; Weersink A; Boucher CA; Hoepelman AI
AIDS; 2003 Jul; 17(10):1572-4. PubMed ID: 12824802
[TBL] [Abstract][Full Text] [Related]
2. Effects of lamivudine on replication of hepatitis B virus in HIV-infected men.
Benhamou Y; Katlama C; Lunel F; Coutellier A; Dohin E; Hamm N; Tubiana R; Herson S; Poynard T; Opolon P
Ann Intern Med; 1996 Nov; 125(9):705-12. PubMed ID: 8929003
[TBL] [Abstract][Full Text] [Related]
3. Characteristics of drug resistant HBV in an international collaborative study of HIV-HBV-infected individuals on extended lamivudine therapy.
Matthews GV; Bartholomeusz A; Locarnini S; Ayres A; Sasaduesz J; Seaberg E; Cooper DA; Lewin S; Dore GJ; Thio CL
AIDS; 2006 Apr; 20(6):863-70. PubMed ID: 16549970
[TBL] [Abstract][Full Text] [Related]
4. [Patients co-infected with HIV and hepatitis-B virus (HBV): the favourable effect of lamivudine, as part of combined antiretroviral therapy, on HBV may be dependent upon the number of CD4-cells].
Smit MC; Haverkamp MH; Weersink AJ; Boucher CA; Hoepelman IM
Ned Tijdschr Geneeskd; 2004 Nov; 148(47):2330-4. PubMed ID: 15587052
[TBL] [Abstract][Full Text] [Related]
5. Evolution of lamivudine-resistant hepatitis B virus and HIV-1 in co-infected individuals: an analysis of the CAESAR study. CAESAR co-ordinating committee.
Pillay D; Cane PA; Ratcliffe D; Atkins M; Cooper D
AIDS; 2000 Jun; 14(9):1111-6. PubMed ID: 10894274
[TBL] [Abstract][Full Text] [Related]
6. Hepatitis B virus drug resistance in HIV-1-infected patients taking lamivudine-containing antiretroviral therapy.
Wongprasit P; Manosuthi W; Kiertiburanakul S; Sungkanuparph S
AIDS Patient Care STDS; 2010 Apr; 24(4):205-9. PubMed ID: 20377434
[TBL] [Abstract][Full Text] [Related]
7. Lamivudine and famciclovir treatment in HIV patients with acute hepatitis B virus infection and hepatitis B reactivation.
Panos GZ; Lampropoulos KM; Angelousi AG; Charatsis GG; Falagas ME
J Clin Gastroenterol; 2007 Feb; 41(2):222-3. PubMed ID: 17245225
[No Abstract] [Full Text] [Related]
8. Viral dynamics in hepatitis B virus infection.
Nowak MA; Bonhoeffer S; Hill AM; Boehme R; Thomas HC; McDade H
Proc Natl Acad Sci U S A; 1996 Apr; 93(9):4398-402. PubMed ID: 8633078
[TBL] [Abstract][Full Text] [Related]
9. Prevalence and characterization of lamivudine-resistant hepatitis B virus mutations in HIV-HBV co-infected individuals.
Cooley L; Ayres A; Bartholomeusz A; Lewin S; Crowe S; Mijch A; Locarnini S; Sasadeusz J
AIDS; 2003 Jul; 17(11):1649-57. PubMed ID: 12853747
[TBL] [Abstract][Full Text] [Related]
10. Long-term outcome of tenofovir disoproxil fumarate use against hepatitis B in an HIV-coinfected cohort.
Alvarez-Uria G; Ratcliffe L; Vilar J
HIV Med; 2009 May; 10(5):269-73. PubMed ID: 19210695
[TBL] [Abstract][Full Text] [Related]
11. Tenofovir for patients with lamivudine-resistant hepatitis B virus (HBV) infection and high HBV DNA level during adefovir therapy.
van Bömmel F; Zöllner B; Sarrazin C; Spengler U; Hüppe D; Möller B; Feucht HH; Wiedenmann B; Berg T
Hepatology; 2006 Aug; 44(2):318-25. PubMed ID: 16871563
[TBL] [Abstract][Full Text] [Related]
12. The management of hepatitis B virus/HIV-1 co-infected patients starting their first HAART regimen. Treating two infections for the price of one drug?
Puoti M; Cozzi-Lepri A; Ancarani F; Bruno R; Ambu S; Ferraro T; Tundo P; Santantonio T; Toti M; Bonasso M; d'Arminio Monforte A; ;
Antivir Ther; 2004 Oct; 9(5):811-7. PubMed ID: 15535419
[TBL] [Abstract][Full Text] [Related]
13. Primary infection with a lamivudine-resistant hepatitis B virus.
Thibault V; Aubron-Olivier C; Agut H; Katlama C
AIDS; 2002 Jan; 16(1):131-3. PubMed ID: 11741175
[No Abstract] [Full Text] [Related]
14. Safety and efficacy of adefovir dipivoxil in patients co-infected with HIV-1 and lamivudine-resistant hepatitis B virus: an open-label pilot study.
Benhamou Y; Bochet M; Thibault V; Calvez V; Fievet MH; Vig P; Gibbs CS; Brosgart C; Fry J; Namini H; Katlama C; Poynard T
Lancet; 2001 Sep; 358(9283):718-23. PubMed ID: 11551579
[TBL] [Abstract][Full Text] [Related]
15. Evidence of long-term suppression of hepatitis B virus DNA by tenofovir as rescue treatment in patients coinfected by HIV.
Quiros-Roldan E; Calabresi A; Lapadula G; Tirelli V; Costarelli S; Cologni G; Zaltron S; Puoti M; Carosi G; Torti C
Antivir Ther; 2008; 13(3):341-8. PubMed ID: 18572746
[TBL] [Abstract][Full Text] [Related]
16. The HBV drug entecavir - effects on HIV-1 replication and resistance.
McMahon MA; Jilek BL; Brennan TP; Shen L; Zhou Y; Wind-Rotolo M; Xing S; Bhat S; Hale B; Hegarty R; Chong CR; Liu JO; Siliciano RF; Thio CL
N Engl J Med; 2007 Jun; 356(25):2614-21. PubMed ID: 17582071
[TBL] [Abstract][Full Text] [Related]
17. In vitro susceptibility of lamivudine-resistant hepatitis B virus to adefovir and tenofovir.
Lada O; Benhamou Y; Cahour A; Katlama C; Poynard T; Thibault V
Antivir Ther; 2004 Jun; 9(3):353-63. PubMed ID: 15259898
[TBL] [Abstract][Full Text] [Related]
18. High incidence of lamivudine-resistance-associated vaccine-escape HBV mutants among HIV-coinfected patients on prolonged antiretroviral therapy.
Pal A; Sarkar N; Saha D; Guha SK; Saha B; Chakrabarti S; Chakravarty R
Antivir Ther; 2015; 20(5):545-54. PubMed ID: 25654813
[TBL] [Abstract][Full Text] [Related]
19. Interference of replication between hepatitis B and C viruses in patients infected with HIV.
Yang RR; Gui X; Chen XY; Zhu Y
J Med Virol; 2011 Jul; 83(7):1159-64. PubMed ID: 21567419
[TBL] [Abstract][Full Text] [Related]
20. Five-year on-treatment efficacy of lamivudine-, tenofovir- and tenofovir + emtricitabine-based HAART in HBV-HIV-coinfected patients.
Kosi L; Reiberger T; Payer BA; Grabmeier-Pfistershammer K; Strassl R; Rieger A; Peck-Radosavljevic M
J Viral Hepat; 2012 Nov; 19(11):801-10. PubMed ID: 23043387
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
